Researchers evaluated a drug that represents a new class of anticoagulants known as Factor XI inhibitors for treating patients with atrial fibrillation as part of the AZALEA-TIMI 71 Study. The trial ...

Patients with atrial fibrillation are typically prescribed an anticoagulant, or blood thinner, to reduce the risk of stroke, but many may discontinue them or never receive a prescription due to ...

Clinically significant reductions in bleeding underscore abelacimab’s strong potential to address an unmet need for patients ...

Researchers have found that Factor XI inhibitors, such as abelacimab, reduce bleeding risks in atrial fibrillation patients more effectively than standard anticoagulants.

Abelacimab, a factor XI inhibitor, demonstrated a 62–69% reduction in major bleeding compared to rivaroxaban in atrial fibrillation patients at moderate-to-high stroke risk, with comparable safety and ...

Subcutaneous injection of abelacimab results in lower levels of free factor XI and significantly fewer bleeding even ...

Three common heart conditions—heart failure, atrial fibrillation, and coronary heart disease—are closely linked to cognitive decline and a higher risk of dementia, according to a new scientific ...

One of the most commonly used types of medication to prevent strokes is blood thinners. These medications reduce the risk of ...

Our Lady of Lourdes Regional Medical Center is embracing cutting-edge technology to transform how heart conditions are ...

Patients with atrial fibrillation are typically prescribed an anticoagulant, or blood thinner, to reduce the risk of stroke, but many may discontinue ...

The temporary pause follows reports of four cases of neurovascular events in the US external evaluation study.

Dr. Ron Aviles explains available procedures and recovery time for those with heart and vascular conditions. Sponsored by Overlake Medical Center and Clinics.